Evidence map›Paper›PMID 26372733›Full record

ArticleOncotarget2015

Expression of prokineticin-receptor2(PK-R2) is a new prognostic factor in human colorectal cancer.

Takanori Goi, Hidetaka Kurebayashi, Yuki Ueda, Takayuki Naruse, Toshiyuki Nakazawa, Kenji Koneri, Yasuo Hirono, Kanji Katayama, Akio Yamaguchi

Open access · diamondAbstract readComparative Study
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Takanori GoiFirst Department of Surgery, University of Fukui, Fukui, Japan.
Hidetaka KurebayashiFirst Department of Surgery, University of Fukui, Fukui, Japan.
Yuki UedaFirst Department of Surgery, University of Fukui, Fukui, Japan.
Takayuki NaruseFirst Department of Surgery, University of Fukui, Fukui, Japan.
Toshiyuki NakazawaFirst Department of Surgery, University of Fukui, Fukui, Japan.
Kenji KoneriFirst Department of Surgery, University of Fukui, Fukui, Japan.
Yasuo HironoFirst Department of Surgery, University of Fukui, Fukui, Japan.
Kanji KatayamaFirst Department of Surgery, University of Fukui, Fukui, Japan.
Akio YamaguchiFirst Department of Surgery, University of Fukui, Fukui, Japan.
University of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increased invasiveness of colorectal cancer cells is important for progression and metastasis to the surrounding organs. According to recent molecular biological studies, signaling through transmembrane Prokineticin-Receptor2(PK-R2) is likely involved in the ability of tumor cell to invade. However, no studies have evaluated the relationship between PK-R2 expression, ability of cancer to invade/metastasize, and patient prognosis in cases of resected colorectal cancer. Accordingly, we have examined these factors in the present study.Immunohistochemical staining was performed to detect PK-R2 in the primary lesion and adjacent normal large intestine mucosa of 324 colorectal cancer patients who underwent resection surgery at our department. Additionally, we conducted clinicopathologic examinations and analyzed patient prognoses with the Kaplan-Meier method. Further, multivariate analysis was conducted using a cox-proportional hazard model.PK-R2 expression was observed on the cellular membrane of the primary lesion in 147 of 324 cases (45.3%) of human colorectal cancer. PK-R2 expression was associated with a higher incidence of vascular invasion, lymph node metastasis, hepatic metastasis, and hematogenous metastasis. Further, prevalence of PK-R2 expression increased as tumor stage increased. In stage III curative resection cases, where recurrence is the most serious problem, cases that expressed PK-R2 had a significantly lower 5-year survival rate (82.1% versus 66.8%) and higher recurrence compared to those cases with no PK-R2 expression. In the multivariate analysis for prognosis, PK-R2 expression was found to be an independent factor(ratio2.621).PK-R2 expression could be one of the new prognostic factors in human colorectal cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesIntestine, LargeLiver NeoplasmsLymphatic MetastasisMaleMiddle AgedNeoplasm GradingBiomarkers, TumorPROKR2 protein, humanReceptors, G-Protein-CoupledReceptors, Peptidecolorectal cancerprognostic factorprokineticin-receptor2

Identifiers

PMID26372733
PMCPMC4741637
OpenAlexW2185640751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.